根据强化期肺结核患者的治疗时间、OAT 类型和 BTA 状态确定贫血程度

Asfina Andini, Siti Aisah, Much Nurkharistna Al Jihad, Edy Soesanto
{"title":"根据强化期肺结核患者的治疗时间、OAT 类型和 BTA 状态确定贫血程度","authors":"Asfina Andini, Siti Aisah, Much Nurkharistna Al Jihad, Edy Soesanto","doi":"10.26714/seanr.6.2.2024.70-78","DOIUrl":null,"url":null,"abstract":"Pulmonary tuberculosis can cause anaemia. Anti-tuberculosis Medications (ATM) are divided into 2 types namely Fixed Dose Combination (FDC) and release. The intensive phase of ATM can cause side effects in mild, moderate, or severe anaemia. This study aims to describe the degree of anaemia in intensive-phase pulmonary TB patients based on the duration of treatment for ATM, type of ATM, and smear status. This research is a retrospective descriptive using secondary data in the form of medical records and the results of the Hb examination in the laboratory. The sampling technique used purposive sampling with inclusion criteria including drug-sensitive pulmonary TB, currently undergoing intensive phase treatment, experiencing anaemia based on the degree of anaemia according to WHO. Exclusion criteria included extrapulmonary TB, drug-resistant TB, and pregnant women. A total of 134 samples and data analysis using univariate analysis. Based on the degree of anaemia, the highest percentage of mild anaemia was during the 2nd week of treatment (60.9%), the type of ATM release (60.0%), and smear-positive (55.3%). The highest percentage of moderate anaemia was in the 6th week (100%), ATM FDC (43.6%), and smear-negative (48.4%). The highest percentage of severe anaemia was at week 8 (50.0%), ATM FDC (6.4%), and smear-negative (6.5%). Worsening of the degree of anaemia as the treatment period progresses, in patients with pulmonary TB who are taking FDC and are smear-negative.","PeriodicalId":250644,"journal":{"name":"South East Asia Nursing Research","volume":"119 19","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Degree of anaemia based on treatment period, type of OAT, and BTA status in intensive-phase pulmonary tuberculosis patients\",\"authors\":\"Asfina Andini, Siti Aisah, Much Nurkharistna Al Jihad, Edy Soesanto\",\"doi\":\"10.26714/seanr.6.2.2024.70-78\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Pulmonary tuberculosis can cause anaemia. Anti-tuberculosis Medications (ATM) are divided into 2 types namely Fixed Dose Combination (FDC) and release. The intensive phase of ATM can cause side effects in mild, moderate, or severe anaemia. This study aims to describe the degree of anaemia in intensive-phase pulmonary TB patients based on the duration of treatment for ATM, type of ATM, and smear status. This research is a retrospective descriptive using secondary data in the form of medical records and the results of the Hb examination in the laboratory. The sampling technique used purposive sampling with inclusion criteria including drug-sensitive pulmonary TB, currently undergoing intensive phase treatment, experiencing anaemia based on the degree of anaemia according to WHO. Exclusion criteria included extrapulmonary TB, drug-resistant TB, and pregnant women. A total of 134 samples and data analysis using univariate analysis. Based on the degree of anaemia, the highest percentage of mild anaemia was during the 2nd week of treatment (60.9%), the type of ATM release (60.0%), and smear-positive (55.3%). The highest percentage of moderate anaemia was in the 6th week (100%), ATM FDC (43.6%), and smear-negative (48.4%). The highest percentage of severe anaemia was at week 8 (50.0%), ATM FDC (6.4%), and smear-negative (6.5%). Worsening of the degree of anaemia as the treatment period progresses, in patients with pulmonary TB who are taking FDC and are smear-negative.\",\"PeriodicalId\":250644,\"journal\":{\"name\":\"South East Asia Nursing Research\",\"volume\":\"119 19\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-07-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"South East Asia Nursing Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.26714/seanr.6.2.2024.70-78\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"South East Asia Nursing Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26714/seanr.6.2.2024.70-78","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

肺结核可导致贫血。抗结核药物(ATM)分为两种类型,即固定剂量复方制剂(FDC)和释放制剂。抗结核药物的强化阶段可引起轻度、中度或重度贫血的副作用。本研究旨在描述强化期肺结核病人的贫血程度,其依据是ATM的治疗时间、ATM的类型和涂片情况。本研究是一项回顾性描述性研究,采用病历形式的二手数据和实验室血红蛋白检查结果。抽样技术采用目的性抽样,纳入标准包括对药物敏感的肺结核患者、正在接受强化阶段治疗的患者、根据世界卫生组织规定的贫血程度出现贫血的患者。排除标准包括肺外结核病、耐药结核病和孕妇。共 134 个样本,采用单变量分析法进行数据分析。根据贫血程度,轻度贫血比例最高的是治疗的第 2 周(60.9%)、ATM 释放类型(60.0%)和涂片阳性(55.3%)。中度贫血比例最高的是第 6 周(100%)、ATM FDC(43.6%)和涂片阴性(48.4%)。重度贫血比例最高的是第 8 周(50.0%)、ATM FDC(6.4%)和涂片阴性(6.5%)。服用 FDC 且涂片阴性的肺结核患者的贫血程度随着治疗时间的延长而加重。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Degree of anaemia based on treatment period, type of OAT, and BTA status in intensive-phase pulmonary tuberculosis patients
Pulmonary tuberculosis can cause anaemia. Anti-tuberculosis Medications (ATM) are divided into 2 types namely Fixed Dose Combination (FDC) and release. The intensive phase of ATM can cause side effects in mild, moderate, or severe anaemia. This study aims to describe the degree of anaemia in intensive-phase pulmonary TB patients based on the duration of treatment for ATM, type of ATM, and smear status. This research is a retrospective descriptive using secondary data in the form of medical records and the results of the Hb examination in the laboratory. The sampling technique used purposive sampling with inclusion criteria including drug-sensitive pulmonary TB, currently undergoing intensive phase treatment, experiencing anaemia based on the degree of anaemia according to WHO. Exclusion criteria included extrapulmonary TB, drug-resistant TB, and pregnant women. A total of 134 samples and data analysis using univariate analysis. Based on the degree of anaemia, the highest percentage of mild anaemia was during the 2nd week of treatment (60.9%), the type of ATM release (60.0%), and smear-positive (55.3%). The highest percentage of moderate anaemia was in the 6th week (100%), ATM FDC (43.6%), and smear-negative (48.4%). The highest percentage of severe anaemia was at week 8 (50.0%), ATM FDC (6.4%), and smear-negative (6.5%). Worsening of the degree of anaemia as the treatment period progresses, in patients with pulmonary TB who are taking FDC and are smear-negative.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Application of aromatherapy to treat PONV in patients post neurosurgery Bibliometric analysis of publication trends of bullying interventions in preschool age children Degree of anaemia based on treatment period, type of OAT, and BTA status in intensive-phase pulmonary tuberculosis patients Impact of Single vs Combination Anti-Hyperglycemic Drug Therapy on HbA1c Levels: A Cross-Sectional Study Effect of recorded maternal voice on procedure pain - a double blinded randomized controlled trial
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1